Get started
Biofrontera Inc.Biofrontera Inc.Biofrontera Inc.

Biofrontera Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

BFRI trade ideas

BFRI - Biotech long playBiofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi. Disclaimer: This is not financial advice. BFRI Stock Insight: Navigating Through Potential and Risks BFRI presents a unique investment opportunity, characterized by significant upcoming events and a favorable market position. Here’s a strategic analysis tailored for BFRI, considering the latest information: Anticipated Catalysts: Looking forward to 2024, BFRI is positioned to encounter two major catalysts. These events could potentially drive significant interest and movement in the stock’s price, highlighting the importance of staying informed on these developments. Low Shares Float: With a shares float of 4.686 million, BFRI is categorized under low-float stocks. This characteristic often leads to higher volatility and quicker price movements, making it a critical factor for investors to consider. Passive Investment Interest: The presence of considerable passive stakes in BFRI suggests a level of confidence from long-term investors. This could indicate underlying value or potential in the company that has attracted passive investment strategies. Market Sentiment Dependency: As with many speculative plays, the success of investments in BFRI heavily relies on a bullish overall market sentiment. Should a market correction occur, it might impact the effectiveness and potential gains of this investment strategy. Technical Analysis Highlights: Key Resistance at $2.0: Overcoming this resistance level is essential for BFRI to unlock further upward momentum. This level serves as a pivotal point for potential price increases. Entry and Risk Management: Stop Loss (SL) Recommendation: A stop loss below $1.0 is advisable to manage risks associated with unforeseen market turns or company-specific setbacks. Take Profit (TP) Targets: Profit-taking levels are tentatively set at approximately $2.7 and $3.5, aiming to capitalize on the anticipated upward movement while managing exposure. Chart Analysis: The provided chart analysis offers vital insights into BFRI's price action, support and resistance levels, and other technical indicators. It’s a valuable tool for identifying potential entry and exit points, based on the stock's historical and current performance. Trading Strategy: Given BFRI's low float and the speculative nature of its upcoming catalysts, a cautious approach is recommended. Investors should closely monitor market sentiment and be prepared to adjust their strategies in response to both the general market environment and specific developments related to BFRI.
NASDAQ:BFRILong
by meitshels_smell_trades
BFRI - I See You - I'm a BuyerBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
NASDAQ:BFRILong
by DivergenceSeeker
$BFRI Next Target PT 10 and higherBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$BFRI – SI 83% High short interest according to S3: $BFRI – SI 83% Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
BFRI squeezing higherBiofrontera Inc., BFRI, is a biopharmaceutical company that develops and provides dermatological products for the treatment of skin diseases in the US. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. BFRI is currently one of the most shorted stocks with some sources stating 84.91% of the free float as short. The price is up more than 400% and the majority of short positions are under water.
NASDAQ:BFRILong
by stensgaard81
$BFRI entry PT 6 Target PT 11-20 and higherNote: ER 11/30 Tues Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans. Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$BFRIBiofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD